Safety and Efficacy Study of Three Different Dosages of NewGam in Patients With CIDP

Inclusion Criteria: * Patients diagnosed as having CIDP based on fulfilment of clinical criteria of the INCAT Group and the definite electrophysiological criteria for CIDP ; patients with MADSAM or pure motor CIDP will be included provided they fulfil these criteria * Worsening of disability and objective increase in weakness or sensory deficit during the 6 months prior to screening * \>=18 years of age Exclusion Criteria: * Unifocal forms of CIDP * Pure sensory CIDP * MMN with conduction block * Treatment of CIDP with immunoglobulins (intravenous or subcutaneous) at any time prior to study entry * Steroids of any type equivalent to prednisolone or prednisone \> 10 mg/day or equivalent plasma exchange (PE) during the last 3 months prior to baseline visit * Treatment with cyclosporin, methotrexate, mitoxantrone, mycophenolate mofetil, interferon or other immunosuppressive or immunomodulatory drugs during the three months prior to baseline visit * Clinical evidence of peripheral neuropathy from another * Known diabetes mellitus * Other serious medical condition complicating assessment or treatment * Thromboembolic events: patients with a history of deep vein thrombosis (DVT) within the last year prior to baseline visit or pulmonary embolism ever * Known IgA deficiency with antibodies to IgA * History of hypersensitivity, anaphylaxis or severe systemic response to immunoglobulin, blood or plasma derived products, or any component of NewGam * Known blood hyperviscosity